ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BCEL Atreca Inc

0.15
0.00 (0.00%)
15 Aug 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Atreca Inc NASDAQ:BCEL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.15 0.16 0.17 0 01:00:00

Atreca to Present at Two Upcoming Virtual Healthcare Conferences

05/08/2020 9:30pm

GlobeNewswire Inc.


Atreca (NASDAQ:BCEL)
Historical Stock Chart


From Aug 2019 to Aug 2024

Click Here for more Atreca Charts.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences:

2020 Wedbush PacGrow Healthcare Virtual ConferenceWednesday, August 12, 2020Presentation time: 2:20 p.m. EDT

Canaccord Genuity 40th Annual Growth ConferenceThursday, August 13, 2020Presentation time: 4:00 p.m. EDT

Live webcasts of each event can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays of the webcasts will be available on the Company's website for 90 days following the live presentations.

About Atreca, Inc.Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

ContactsAtreca, Inc. Herb Cross Chief Financial Officer info@atreca.com

Investors: Alex Gray, 650-779-9251, ext. 251 agray@atreca.com

Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com

Source: Atreca, Inc.

1 Year Atreca Chart

1 Year Atreca Chart

1 Month Atreca Chart

1 Month Atreca Chart